GlassScriptPhysician profile
Mary Jane Rorick
NPI 1407016306
$14,219.12
in general payments reported to CMS, 2019-2025
30 companies · $712 in 2025
The $712 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,818 · 2023: $5,219 · 2024: $4,470 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $89.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,311.07 |
| Education | $89.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,802.13 | 2022-2025 | Saphnelo |
| Amgen INC. | $1,659.16 | 2022-2025 | Enbrel, Otezla, Krystexxa |
| Ucb, INC. | $1,641.34 | 2022-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $1,465.69 | 2022-2025 | |
| Janssen Biotech, INC. | $1,145.01 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $831.34 | 2022-2024 | Benlysta |
| Horizon Therapeutics Plc | $745.62 | 2022-2023 | Krystexxa |
| Lilly USA, LLC | $707.55 | 2022-2024 | Taltz, Olumiant |
| Janssen Scientific Affairs, LLC | $527.21 | 2022-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $475.95 | 2022-2025 | |
| Organon LLC | $442.73 | 2022-2025 | Renflexis, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.22 | 2022-2025 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $363.93 | 2022-2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $319.67 | 2022-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $290.73 | 2022-2024 | Purified Cortrophin Gel |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $269.74 | 2022-2024 | |
| Genentech USA, INC. | $168.95 | 2022-2025 | Actemra |
| Actelion Pharmaceuticals US, INC. | $166.79 | 2022-2023 | Opsumit, Uptravi |
| Kyowa Kirin, INC. | $151.86 | 2024-2025 | Crysvita |
| Fresenius Kabi USA, LLC | $146.16 | 2023-2024 | Idacio |
| Radius Health, INC. | $107.41 | 2024-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $100.52 | 2022-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $94.03 | 2022-2024 | Ultomiris |
| Sandoz INC. | $56.19 | 2023-2024 | Hyrimoz |
| Scilex Pharmaceuticals INC. | $31.78 | 2024 | |
| Genzyme Corporation | $24.30 | 2023 | |
| Nalu Medical, INC. | $20.25 | 2023 | Nalu Neurostimulation System |
| Sobi, INC | $16.86 | 2023 | |
| Celltrion USA INC. | $15.79 | 2023 | Yuflyma |
| Octapharma USA, INC. | $14.21 | 2023 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Jane Rorick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.